Literature DB >> 23094724

Peripheral mechanisms in irritable bowel syndrome.

Michael Camilleri1.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23094724     DOI： 10.1056/NEJMra1207068

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  107 in total

1.  Treating Irritable Bowel Syndrome: A Fresh and Minty Approach to an Old Therapy.

Authors:  Lucinda A Harris
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

2.  High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome.

Authors:  Keren Hod; Tamar Ringel-Kulka; Christopher F Martin; Nitsan Maharshak; Yehuda Ringel
Journal:  J Clin Gastroenterol       Date:  2016-03       Impact factor: 3.062

3.  Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit.

Authors:  Michael Camilleri; Eric W Klee; Andrea Shin; Paula Carlson; Ying Li; Madhusudan Grover; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-07       Impact factor: 4.052

4.  RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study.

Authors:  Michael Camilleri; Paula Carlson; Andres Acosta; Irene Busciglio; Asha A Nair; Simon J Gibbons; Gianrico Farrugia; Eric W Klee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-24       Impact factor: 4.052

5.  Mechanisms of Probiotic VSL#3 in a Rat Model of Visceral Hypersensitivity Involves the Mast Cell-PAR2-TRPV1 Pathway.

Authors:  Ying-Jie Li; Cong Dai; Min Jiang
Journal:  Dig Dis Sci       Date:  2018-12-17       Impact factor: 3.199

6.  IBS: biomarkers for IBS: ready for prime time?

Authors:  Giovanni Barbara
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

7.  Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS.

Authors:  Hilary Schenck Eidam; John Russell; Kaushik Raha; Michael DeMartino; Donghui Qin; Huiping Amy Guan; Zhiliu Zhang; Gong Zhen; Haiyu Yu; Chengde Wu; Yan Pan; Gerard Joberty; Nico Zinn; Sylvie Laquerre; Sharon Robinson; Angela White; Amanda Giddings; Ehsan Mohammadi; Beverly Greenwood-Van Meerveld; Allen Oliff; Sanjay Kumar; Mui Cheung
Journal:  ACS Med Chem Lett       Date:  2018-05-24       Impact factor: 4.345

8.  Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.

Authors:  Raffaele Capasso; Pierangelo Orlando; Ester Pagano; Teresa Aveta; Lorena Buono; Francesca Borrelli; Vincenzo Di Marzo; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

9.  Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.

Authors:  Johanna Iturrino; Michael Camilleri; Irene Busciglio; Duane Burton; Alan R Zinsmeister
Journal:  Dig Liver Dis       Date:  2013-10-04       Impact factor: 4.088

10.  Conditioned pain modulation in women with irritable bowel syndrome.

Authors:  Monica E Jarrett; Robert J Shulman; Kevin C Cain; Wimon Deechakawan; Lynne T Smith; Philippe Richebé; Margaret Eugenio; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2014-01-24       Impact factor: 2.522
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.